COR · 8-K · 20260805PR000032

Liquidity and Debt Position

Cencora, Inc. · 2026-08-05 · Importance 89 · Surprise 82 · No source text

Cash and cash equivalents declined to $2.815 billion at June 30, 2026, from $4.356 billion at September 30, 2025. Long-term debt increased to $11.444 billion from $7.543 billion, and short-term debt increased to $279.2 million from $117.8 million. Nine-month net debt borrowings were $3.730 billion, including $3.0 billion of senior notes and $1.5 billion of term loans used to finance OneOncology. Net interest expense increased 72.0% year over year to $140.7 million in the quarter, primarily because of acquisition financing and lower interest income.

Key facts

• In the nine months ended June 30, 2026 financing activities included issuance of $3.0 billion of senior notes and $1.5 billion of term loans to finance a portion of the February 2, 2026 acquisition of OneOncology source
• Total assets as of June 30, 2026: $83,805,553 thousand source
• Long-term debt as of June 30, 2026: $11,444,086 thousand; short-term debt: $279,155 thousand source
• Cash and cash equivalents as of June 30, 2026: $2,815,291 thousand source
• Third quarter fiscal 2026 net interest expense: $140.7 million, an increase of $58.9 million from prior year quarter source
• Third quarter fiscal 2026 ended June 30, 2026 source

Impact estimates